Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Pfizer, Alnylam, AngioLab, Novartis, BeiGene, CytoDyn, Eli Lilly, Galectin, Hepagene

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 110+ key pharma and biotech companies are working on 160+ pipeline drugs in the Non-Alcoholic Fatty Liver Disease (NAFLD) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Alcoholic Fatty Liver Disease Therapeutics Market.

The report provides a detailed description of the Non-Alcoholic Fatty Liver Disease drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Non-Alcoholic Fatty Liver Disease Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Non-Alcoholic Fatty Liver Disease therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Fatty Liver Disease treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Non-Alcoholic Fatty Liver Disease drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Non-Alcoholic Fatty Liver Disease treatment market.

Learn More about the Clinical and Commercial Development Activities in the Non-Alcoholic Fatty Liver Disease Therapeutics Domain @
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Analysis
Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver. It is the most common chronic liver disease, affecting at least a quarter of the global adult population. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD associated with persistent liver cell injury leading to fibrosis and in a subset may progress to cirrhosis and end-stage liver disease.

Presently, there are no FDA, EMA, or PMDA (Pharmaceuticals and Medical Devices Agency) approved for the treatment of NASH, however, researchers are studying medicines that may improve these conditions. The current treatment The current front-line treatment consists of lifestyle modifications, such as diet and exercise. Additional treatment options for NASH, aside from lifestyle modifications, have included off-label use of vitamin E and anti-diabetes agents (e.g., pioglitazone and liraglutide).

There are approx. 110+ key companies developing therapies for Non-Alcoholic Fatty Liver Disease. Currently, Inventiva Pharma is leading the therapeutics market with its Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage of clinical development.

Non-Alcoholic Fatty Liver Disease (NAFLD) Companies in the Therapeutics Market Include:
Afimmune, Alnylam Pharmaceuticals, Inc., AngioLab, AstraZeneca, BeiGene, Can Fite Biopharma, Chemomab Therapeutics, Cirius Therapeutics, CytoDyn, Inc., Dr. Falk Pharma GmbH, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, HK inno.N, Inventiva Pharma, Ionis Pharmaceuticals, Kowa Pharmaceutical, Lipocine, Inc., MediciNova, Metacrine, Inc., Mitsubishi Tanabe Pharma, NorthSea Therapeutics, Novartis Pharmaceuticals, Novo Nordisk, NuSirt Biopharma, Oramed Pharmacetuicals, Pfizer, Poxel SA, Rivus Pharmaceuticals, Sagimet Biosciences, Sinew Pharma, Terns Pharmaceuticals, Viking Therapeutics, and many others.

Emerging and Marketed Non-Alcoholic Fatty Liver Disease (NAFLD) Therapies Covered in the Report Include:
• ALS-L1023: AngioLab
• Belapectin: Galectin Therapeutics
• Lanifibranor: Inventiva Pharma
• MGL-3196 (Resmetirom): Madrigal Pharmaceuticals
• MN-001: MediciNova
• Pegozafermin: 89bio, Inc.
• Tirzepatide: Eli Lilly and Company
• TVB-2640: Sagimet Biosciences
• ZED 1227: Dr. Falk Pharma GmbH
And Many More

Get an in-depth Assessment of the Emerging Therapies and Non-Alcoholic Fatty Liver Disease Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Mechanism of Action of the Emerging Therapies
• Ribosomal protein S6 kinase modulators
• Thyroid hormone receptor beta agonist
• Mitochondrial membrane transport protein modulators
• RNA interference
• Thyroid hormone receptor beta agonists
• Fatty acid synthetase complex inhibitors
• Transglutaminase 2 inhibitors
• Fibroblast growth factor receptor agonists
• Serotonin 2A receptor antagonist
• Rho-associated kinase inhibitors
• Sodium-bile acid cotransporter inhibitors
• NF E2 related factor 2 stimulants

The Report Covers the Emerging Non-Alcoholic Fatty Liver Disease Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Non-Alcoholic Fatty Liver Disease Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease Current Treatment Patterns
4. Non-Alcoholic Fatty Liver Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease Late-Stage Products (Phase-III)
7. Non-Alcoholic Fatty Liver Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Fatty Liver Disease Discontinued Products
13. Non-Alcoholic Fatty Liver Disease Product Profiles
14. Non-Alcoholic Fatty Liver Disease Companies
15. Non-Alcoholic Fatty Liver Disease Drugs
16. Dormant and Discontinued Products
17. Non-Alcoholic Fatty Liver Disease Unmet Needs
18. Non-Alcoholic Fatty Liver Disease Future Perspectives
19. Non-Alcoholic Fatty Liver Disease Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.